New shot aims to tame bleeding disorder in small trial

NCT ID NCT07640893

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests an injection called SR604 in 24 adults with von Willebrand disease, a bleeding disorder. The goal is to see if it safely reduces the number of bleeding episodes. Participants receive multiple doses, and researchers track bleeding rates and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SR604 injection
What this could lead to
If successful, this could provide a new treatment option to control bleeding episodes in people with von Willebrand disease.
What could go wrong
This is an early Phase 2 trial with only 24 participants, so results may not apply to everyone. The treatment may not reduce bleeding as hoped or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VON WILLEBRAND DISEASE (VWD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Henan Provincial People's Hospital

    RECRUITING

    Zhengzhou, China

  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences

    RECRUITING

    Tianjin, China

  • Jinan Central Hospital

    RECRUITING

    Jinan, China

  • North China University of Science and Technology Affiliated Hospital

    RECRUITING

    Tangshan, China

  • The First Affiliated Hospital of Guangxi Medical University

    RECRUITING

    Nanning, China

  • The First Affiliated Hospital of Soochow University

    RECRUITING

    Suzhou, China

  • The First Affiliated Hospital of University of Science and Technology of China

    RECRUITING

    Hefei, China

  • The Second Hospital of Shanxi Medical University

    RECRUITING

    Taiyuan, China

  • Xiangya Hospital of Central South University

    RECRUITING

    Changsha, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.